Clinical Trial Update: Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oblimersen in combination with interferon alfa for metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Genasense (oblimersen)
• Interferon Alfa (interferon alfa)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer | Phase 2 | Status: COMPLETED